Table 1.
Experiment 1 |
p | Experiment 2 |
|||||
---|---|---|---|---|---|---|---|
CON-TREX (n=22) | TREX1 (n=20) | TREX2 (n=21) | CONWHL (n=21) | WHL (n=20) | p | ||
No. mice with mammary carcinoma*,† | 19/22 (86%) | 19/20 (95%) | 21/21 (100%) | 0.26 | 16/21 (76%) | 20/20 (100%) | 0.05 |
No. mice with mammary carcinoma in >1 gland | 5/19 (26%) | 11/19 (58%) | 14/21 (67%) ‡ | 0.03 | 8/16 (50%) | 16/20 (80%) | 0.08 |
No. mice with mammary carcinoma metastasis in lung | 6/19 (27%) | 4/19 (21%) | 5/21 (24%) | 0.81 | 1/16 (6%) | 6/20 (30%) | 0.10 |
TUMOR GROWTH § | CON-TREX (n=19) | TREX1 (n=13) | TREX2 (n=17) | p | CONWHL (n=16) | WHL (n=20) | p |
Time to 1.5 cm tumor (days; mean ± SE) | 24.8 ± 1.1 | 13.8 ± 1.2‡ | 19.5 ± 1.1 | 0.02 | 17.2 ± 1.1 | 22.5 ± 1.1 | 0.10 |
Other causes of sacrifice/death included: CON-TREX-adrenal pheochromocytoma, lipoma, end of study; TREX1-end of study; CON-WHL-T-cell lymphoma, sarcoma (n=3), end of study.
Additional, non-mammary gland neoplasms: CON-TREX-sarcoma, clitoral gland carcinoma, rhabdomyosarcoma; TREX1-lymphoma.
p<0.05 vs. CON-TREX
Includes only mice not censored in the survival analysis. Log transformed data used in the statistical analysis due to non-normal distribution; geometric means presented in table.